Oral nanoparticles of SNX10-shRNA plasmids ameliorate Mouse Colitis. W.Bao, Q.Wu, B.Hu, D.Sun, S.Zhao, X.Shen, H.Cheng & W.Shen. Int J Nanomedicine, 2021 -01; Volume 16:345.
IBD is a chronic disease characterized by inflammation of the gastrointestinal tract, but its pathogenesis remains elusive. Therefore, it is necessary to identify new therapeutic targets.
Sorting nexins (SNXs) are proteins involved in protein sorting, transmembrane transport and membrane remodelling. Previous studies have shown that under-expression of SNX10 results in an inhibition of ulcerative colitis. This may be linked to relief of intestinal inflammation and mucosal damage.
Moreover, researchers have described a correlation between SNX10 deficiency and changes in epithelial cells. As epithelial cells constitute the mucosal barrier system, these changes could be related to intestinal instability. These results suggest that SNX10 deletion could be an effective mechanism for IBD treatment.
Continuing with this research line, in this article, authors have silenced SNX10 RNAs in mice mimicking chronic IBD conditions using oral nanoparticles. The results showed a reduced body-weight loss and relieved intestinal damage on the model animals. This study paves the way for exploring new therapeutic options using these shRNA nanoparticles targeting SNX10.